Xeris Biopharma Holdings

NasdaqGS:XERS Stock Report

Mkt Cap: US$179.5m

Xeris Biopharma Holdings Financial Health

How is Xeris Biopharma Holdings's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: XERS's short term assets ($148.9M) exceed its short term liabilities ($68.6M).

Long Term Liabilities: XERS's short term assets ($148.9M) do not cover its long term liabilities ($179.4M).


Debt to Equity History and Analysis

Debt Level: XERS's net debt to equity ratio (81.9%) is considered high.

Reducing Debt: Insufficient data to determine if XERS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XERS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XERS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies